Citation Impact
Citing Papers
The Bypass Angioplasty Revascularization Investigation 2 Diabetes Randomized Trial of Different Treatment Strategies in Type 2 Diabetes Mellitus With Stable Ischemic Heart Disease
2009
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
Ten-Year Follow-Up Survival of the Medicine, Angioplasty, or Surgery Study (MASS II)
2010
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
2014 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
Impact of different exercise training modalities on the coronary collateral circulation and plaque composition in patients with significant coronary artery disease (EXCITE trial): study protocol for a randomized controlled trial
2012
Computed Fractional Flow Reserve (FFTCT) Derived from Coronary CT Angiography
2013
A Randomized Controlled Trial of a Discharge Nursing Intervention to Promote Self-Regulation of Care for Early Discharge Interventional Cardiology Patients
2011
Fourth Universal Definition of Myocardial Infarction (2018)
2018 Standout
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
The Acute Risks of Exercise in Apparently Healthy Adults and Relevance for Prevention of Cardiovascular Events
2016
Sarcopenia: a chronic complication of type 2 diabetes mellitus
2018 Standout
The Myth of the “Vulnerable Plaque”
2015
The changing landscape of atherosclerosis
2021 StandoutNature
Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association
2021 Standout
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
2013 Standout
Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association
2019
Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial
2013 Standout
Are the Culprit Lesions Severely Stenotic?
2013
Functional assessment of coronary stenoses: can we live without it?
2012
High-Risk Coronary Atheroma
2013
Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)
2011
Coronary revascularization in diabetic patients
2012
Atherosclerosis
2019 Standout
Third Universal Definition of Myocardial Infarction
2012 Standout
Elevated serum interleukin-6 is predictive of coronary artery disease in intermediate risk overweight patients referred for coronary angiography
2017
Exercise-based cardiac rehabilitation for coronary heart disease
2011 Standout
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)
2011 Standout
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association
2017 Standout
Impact of renal failure on all-cause mortality and other outcomes in patients treated by percutaneous coronary intervention
2015
Key challenges for delivering clinical impact with artificial intelligence
2019 Standout
Cost-Effectiveness of Transcatheter Aortic Valve Replacement Compared With Standard Care Among Inoperable Patients With Severe Aortic Stenosis
2012
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical Practice Guideline
2013 Standout
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Mechanisms of Plaque Formation and Rupture
2014 Standout
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
Cardiac Disease Evaluation and Management Among Kidney and Liver Transplantation Candidates
2012
Interventions for enhancing medication adherence
2014 Standout
Global Coronary Flow Reserve Is Associated With Adverse Cardiovascular Events Independently of Luminal Angiographic Severity and Modifies the Effect of Early Revascularization
2014
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Fourth Universal Definition of Myocardial Infarction (2018)
2018 Standout
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Fourth universal definition of myocardial infarction (2018)
2018 Standout
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Nonobstructive Coronary Artery Disease and Risk of Myocardial Infarction
2014
Works of Marcin Dada being referenced
Influence of chronic exercise on carotid atherosclerosis in marathon runners
2014
Impact of Optimal Medical Therapy With or Without Percutaneous Coronary Intervention on Long-Term Cardiovascular End Points in Patients With Stable Coronary Artery Disease (from the COURAGE Trial)
2009
Impact of Metabolic Syndrome and Diabetes on Prognosis and Outcomes With Early Percutaneous Coronary Intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) Trial
2011
Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial
2006
Changes in muscle strength in individuals with statin-induced myopathy: A summary of 3 investigations
2015
Predicting Outcome in the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation)
2014
Optimal Medical Therapy With or Without Percutaneous Coronary Intervention for Patients With Stable Coronary Artery Disease and Chronic Kidney Disease
2009
Gated myocardial perfusion single photon emission computed tomography in the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial, Veterans Administration Cooperative study no. 424
2006
Optimal Medical Therapy With or Without Percutaneous Coronary Intervention in Older Patients With Stable Coronary Disease
2009
Cost-Effectiveness of Percutaneous Coronary Intervention in Optimally Treated Stable Coronary Patients
2008
Angiographic Disease Progression and Residual Risk of Cardiovascular Events While on Optimal Medical Therapy
2011